Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$9.99 - $18.71 $132,867 - $248,843
-13,300 Reduced 7.15%
172,600 $3.2 Million
Q2 2023

Aug 14, 2023

BUY
$9.17 - $19.29 $679,497 - $1.43 Million
74,100 Added 66.28%
185,900 $2.06 Million
Q1 2023

May 15, 2023

SELL
$12.53 - $21.71 $692,909 - $1.2 Million
-55,300 Reduced 33.09%
111,800 $1.5 Million
Q4 2022

Feb 14, 2023

SELL
$11.61 - $16.11 $1.96 Million - $2.72 Million
-169,000 Reduced 50.28%
167,100 $2.07 Million
Q3 2022

Nov 14, 2022

BUY
$12.21 - $19.7 $2.23 Million - $3.59 Million
182,400 Added 118.67%
336,100 $4.69 Million

Others Institutions Holding ICPT

About INTERCEPT PHARMACEUTICALS, INC.


  • Ticker ICPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,127,400
  • Description
  • Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...
More about ICPT
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.